People: Antares Pharma Inc (ATRS.O)

ATRS.O on Consolidated Issue listed on NASDAQ Capital Market

2.08USD
27 Aug 2014
Price Change (% chg)

$-0.04 (-1.93%)
Prev Close
$2.12
Open
$2.10
Day's High
$2.11
Day's Low
$2.06
Volume
282,407
Avg. Vol
1,311,012
52-wk High
$5.15
52-wk Low
$1.87

Search Stocks

Summary

Name Age Since Current Position

Leonard Jacob

65 2008 Independent Chairman of the Board

Eamonn Hobbs

55 2014 President, Chief Executive Officer, Director

Robert Apple

47 2009 Chief Financial Officer, Executive Vice President, President - Parenteral Products Division

Jennifer Stacey

2014 Senior Vice President, General Counsel, Human Resources and Secretary

Robert Roche

58 2013 Director

Marvin Samson

72 2013 Director

Thomas Garrity

65 2003 Independent Director

Jacques Gonella

72 2008 Independent Director

Anton Gueth

57 2003 Independent Director

Biographies

Name Description

Leonard Jacob

Dr. Leonard S. Jacob M.D., Ph.D., is an Independent Chairman of the Board of Antares Pharma Inc since October 2008. Dr. Jacob joined the Board of Directors in January 2007 and is the Chairman of Governance and Nominating Committee and is a member of Compensation Committee. In 2006, Dr. Jacob was named Chairman of the Board of Bradley Pharmaceuticals which was subsequently acquired by Nycomed. He founded InKine Pharmaceutical Company Inc. in 1997 and served as Chairman and CEO from its founding until the company was acquired by Salix Pharmaceuticals in 2005. In 1989, Dr. Jacob co-founded Maganin Pharmaceuticals and served as its Chief Operating Officer until 1996. From 1980 to 1989, Dr. Jacob served in a variety of executive roles including Worldwide Vice President of SmithKline & French Labs (now Glaxo-SmithKline) and as a member of their Corporate Management Committee. He earned a Ph.D. in pharmacology from Temple University School of Medicine and an M.D. from the Medical College of Pennsylvania (Drexel University College of Medicine). Dr. Jacob currently serves as Chairman of Life Science Advisors, a consulting group to the healthcare industry. He also serves on the Board of Directors of QuiqMeds, a private digital drug dispensing company, the Colon Cancer Alliance, the Board of Overseers for Temple University School of Medicine, the Board of Trustees of the University of the Sciences in Philadelphia and he was a founding Director of the Jacob Internet fund, a public mutual fund where he served from 1999 to 2010.

Eamonn Hobbs

Mr. Eamonn P. Hobbs is President, Chief Executive Officer, Director of Antares Pharma Inc. Mr. Hobbs has over 30 years of experience in the medical device, pharmaceutical and combination products industry, including the medical specialty fields of radiology, vascular surgery, interventional cardiology, oncology and gastroenterology. From 2009 to 2013 Mr. Hobbs served as President and Chief Executive Officer of Delcath Systems, Inc., a NASDAQ traded specialty pharmaceutical and medical device company specializing in cancer treatment. Prior to Delcath Systems, Inc., Mr. Hobbs served as President and Chief Executive Officer of AngioDynamics, Inc., a NASDAQ traded company he co-founded in 1988 as a subsidiary of E-Z-EM. Throughout his 21 year tenure at AngioDynamics, he led efforts in marketing, strategic planning, product development and general management. From 1988 to 2004, Mr. Hobbs also served as Executive Vice President of Business Development of E-Z-EM, a NASDAQ traded company. Before joining AngioDynamics/ E-Z-EM, Mr. Hobbs was Director of Marketing and Product Development at NAMIC; founder, President and Chief Executive Officer of Hobbs Medical, Inc; and a Product Development Engineer at Cook Incorporated. Mr. Hobbs is the immediate past Chairman of the Board of Directors of the Medical Device Manufacturers Association. Mr. Hobbs received a Bachelor of Science in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts (Lowell).

Robert Apple

Mr. Robert F. Apple CPA., is Chief Financial Officer, Executive Vice President, President -Parenteral Products Division of Antares Pharma Inc. He joined the Company in February 2006 as Senior Vice President, Chief Financial Officer and Corporate Secretary. Prior to joining the Company, Mr. Apple served as Chief Operating and Financial Officer at InKine Pharmaceutical Company, Inc. from 2003 to 2005, and Chief Financial Officer from 1997 to 2002. From 1995 to 1997, Mr. Apple was employed by Genaera Corporation, Inc., a biotechnology company, where he held the position of Corporate Controller. From May 1994 until July 1995, Mr. Apple was employed by Liberty Technologies, Inc. as Corporate Controller. Prior to May 1994, Mr. Apple held various positions of increasing responsibility at Arthur Andersen & Company LLP. He holds a B.A. degree in accounting from Temple University and is a CPA. Mr. Apple also serves on the Board of Directors of Kerathin, LLC, a private medical device company in the podiatry field.

Jennifer Stacey

Ms. Jennifer Evans Stacey, Esq. is Senior Vice President, General Counsel, Human Resources and Secretary of the Company. Jennifer has a diversified corporate background including 20 years of experience in the pharmaceutical industry. Ms. Stacey graduated with a BA from Princeton University and obtained her JD from University of Pennsylvania Law School. Jennifer comes to Antares Pharma from FXI, Inc. where she served as Senior Vice President, General Counsel, Secretary and Human Resources from November 2012 until May 2014. From January 2005 until February 2012, Ms. Stacey served as Executive Vice President, General Counsel, Human Resources and Secretary at Auxilium Pharmaceuticals, Inc. Prior to that, Ms. Stacey was Senior Vice President, Corporate Communications, and General Counsel of Aventis Behring LLC, a leader in the $6.1 billion global plasma-protein business and a wholly owned subsidiary of Aventis. Prior to the formation of Aventis Behring, Ms. Stacey was with Rhône-Poulenc Rorer (predecessor company of Aventis), first at its headquarters in Collegeville, PA and then at its offices in Paris, France as International Counsel. Ms. Stacey began her legal career at King & Spalding in Washington, DC, where she served as an associate in the Corporate Finance Department.

Robert Roche

Mr. Robert P. Roche, Jr., is Director of Antares Pharma Inc. He is a member of the Governance and Nominating Committee. He is the founding member of Robert Roche Associates LLC, a consulting firm providing guidance to the pharmaceutical and healthcare industries. He created this firm upon his retirement from Cephalon Inc. in February 2010. He joined Cephalon in January 1995 as the Vice President of Sales and Marketing and was named Executive Vice President, Worldwide Pharmaceutical Operations of Cephalon in 2005. Before joining Cephalon, Mr. Roche served as Director and Vice President, Worldwide Strategic Product Development, for SmithKline Beecham’s central nervous system and gastrointestinal products business. He also was managing director of SmithKline’s pharmaceutical operations in the Philippines. Prior to that, he held senior marketing positions in Canada and Spain and had product planning responsibilities for SmithKline in Latin America. Mr. Roche began his pharmaceutical career in 1982 with SmithKline & French as a U.S. pharmaceutical sales representative. Mr. Roche is a member of the Board of Directors of Civitas Therapeutics of Chelsea, MA, a privately held specialty pharmaceutical company focused on respiratory delivery of small molecule therapeutics. He formerly served as a Director of LiceCell Inc. up until its acquisition in 2008, EKR Therapeutics until its acquisition in 2012 and NuPathe Inc. until its acquisition in 2014. He also serves on the Boards of Bryn Mawr Hospital and Westtown School. He is a graduate of Colgate University and earned an MBA from The Wharton School at the University of Pennsylvania.

Marvin Samson

Mr. Marvin Samson has been appointed as the Director of Antares Pharma, Inc., with effect from May 23, 2013. He was formerly Group Vice President - Worldwide Injectables of Teva, previously having served as CEO and a member of the Board of Directors of Sicor. He was a founder and CEO of Elkins-Sinn, Inc. (now a division of Hikma) and Marsam Pharmaceuticals. He is the founder and CEO of Samson Medical Technologies, a privately held company providing hospital and alternate site pharmacists with injectable drug delivery systems and programs. Mr. Samson is Chairman of The University of Sciences Board of Trustees and serves on the Board of Directors of Flynn Pharma. Mr. Samson served as chairman of the board and CEO of Qualitest Pharmaceuticals prior to its purchase by Endo Pharmaceuticals in late 2010 and as the chairman of the Generic Pharmaceutical Industry Association from 1997 to 2000. Mr. Samson is the holder of five U.S. patents pertaining to pharmaceutical manufacturing. Mr. Samson graduated from Temple University with a B.S. in Chemistry.

Thomas Garrity

Mr. Thomas J. Garrity is an Independent Director of Antares Pharma Inc. He serves as Chairman of Audit Committee and as a member of Governance and Nominating Committee. He was Executive Vice President and Chief Financial Officer for PCS Health Systems, a provider of managed pharmaceutical care, from 1994 to 2000. He played a key role during its subsequent integration with Advance Paradigm, Inc. and became Executive Vice President of Financial Operations for the resultant entity, AdvancePCS, a provider of health improvement solutions. Prior to that, Mr. Garrity held various positions at Eli Lilly and Company, including Director of Public Policy Planning and Development; Director of Corporate Financial Planning; and other international, marketing and financial positions. Mr. Garrity holds a B.S. degree from the Massachusetts Institute of Technology in aerospace engineering and an MBA in finance from the University of Chicago. He is currently a private investor and consultant.

Jacques Gonella

Dr. Jacques Gonella Ph.D., is an Independent Director of Antares Pharma Inc. Dr. Gonella was the founder of Permatec (a Swiss company that was merged with Medi-Ject, Inc., to form Antares Pharma, Inc.) and had served as the Chairman of the Board of Directors of Permatec since its founding in June 1997. Prior to founding Permatec, Dr. Gonella founded JAGO Pharma AG in 1983 and served as its President and Chief Executive Officer until its acquisition in May 1996 by SkyePharma, PLC, a United Kingdom company listed on the London Stock Exchange and quoted on NASDAQ. Prior to the founding of JAGO, Dr. Gonella occupied various positions with F. Hoffman-La Roche Ltd. and Pfizer Inc. He previously served as a member of the Board of Directors of Protherics PLC, London and he currently serves on the Board of Directors of several private companies. He is a private investor and since 1997 has served as proprietor of JG Consulting AG, Switzerland. Dr. Gonella holds a doctorate in analytical chemistry from the Polytechnic Institute of Lausanne, Switzerland.

Anton Gueth

Mr. Anton G. Gueth is an Independent Director of Antares Pharma Inc. He serves as Chairman of Compensation Committee and as a member of Audit Committee and Governance and Nominating Committee.Mr. Gueth is currently President of Gueth Consulting LLC, which focuses on business development and alliance management in the pharmaceutical industry. He was previously a Managing Director of Burrill Securities, a merchant bank specialized in the health care field, and serves currently as Senior Advisor to Burrill Securities under a consulting agreement. Mr. Gueth also serves on the Board of Directors of Spectrum Pharmaceutical, where he is a member of the Audit Committee. His career includes nearly 19 years with Eli Lilly and Company (“Lilly”), most recently as director of Alliance Management. He also served as General Manager of Lilly’s African and Middle Eastern operations; Vice President of Financial Planning and Treasury of PCS Health Systems; Managing Director of Lilly’s Saudi Arabia, Gulf and Yemen operations, as well as other sales, marketing and financial positions. Mr. Gueth earned a Masters Degree in agricultural economics from the Justus Liebig University in Giessen, Germany, as well as a Masters Degree in public affairs from Indiana University. He is a director of the American Liver Foundation, Northern California Chapter.

Basic Compensation

Name Fiscal Year Total

Leonard Jacob

--

Eamonn Hobbs

--

Robert Apple

1,024,650

Jennifer Stacey

--

Robert Roche

--

Marvin Samson

--

Thomas Garrity

--

Jacques Gonella

--

Anton Gueth

--
As Of 30 Dec 2013

Options Compensation

Search Stocks